| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| In Situ Hybridization, Fluorescence | 52 | 2022 | 2510 | 2.280 |
Why?
|
| Proto-Oncogene Proteins c-met | 16 | 2020 | 562 | 2.260 |
Why?
|
| Lung Neoplasms | 72 | 2023 | 13485 | 2.180 |
Why?
|
| Pyrazoles | 22 | 2019 | 2030 | 2.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 40 | 2023 | 5387 | 2.020 |
Why?
|
| Gene Amplification | 26 | 2024 | 1088 | 1.870 |
Why?
|
| Pyridines | 22 | 2021 | 2888 | 1.860 |
Why?
|
| Gene Rearrangement | 20 | 2019 | 1142 | 1.820 |
Why?
|
| Isocitrate Dehydrogenase | 23 | 2019 | 950 | 1.810 |
Why?
|
| Mutation | 129 | 2024 | 30213 | 1.770 |
Why?
|
| Gene Fusion | 11 | 2024 | 356 | 1.760 |
Why?
|
| Adenocarcinoma | 34 | 2019 | 6359 | 1.610 |
Why?
|
| Protein Kinase Inhibitors | 48 | 2023 | 5690 | 1.600 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 29 | 2022 | 1621 | 1.600 |
Why?
|
| High-Throughput Nucleotide Sequencing | 29 | 2024 | 3666 | 1.550 |
Why?
|
| Protein-Tyrosine Kinases | 14 | 2019 | 2426 | 1.490 |
Why?
|
| Drug Resistance, Neoplasm | 35 | 2024 | 5329 | 1.270 |
Why?
|
| Antibodies, Viral | 12 | 2024 | 3212 | 1.190 |
Why?
|
| Bile Duct Neoplasms | 9 | 2023 | 614 | 1.120 |
Why?
|
| Cholangiocarcinoma | 9 | 2023 | 562 | 1.120 |
Why?
|
| Brain Neoplasms | 28 | 2021 | 9101 | 1.010 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 25 | 2023 | 1762 | 0.970 |
Why?
|
| Oncogene Proteins, Fusion | 16 | 2024 | 1609 | 0.940 |
Why?
|
| Proto-Oncogene Proteins B-raf | 22 | 2023 | 2056 | 0.920 |
Why?
|
| Proto-Oncogene Proteins | 22 | 2019 | 4522 | 0.890 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2024 | 300 | 0.850 |
Why?
|
| Glioblastoma | 16 | 2021 | 3458 | 0.840 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 5 | 2024 | 258 | 0.820 |
Why?
|
| Glioma | 16 | 2019 | 3498 | 0.810 |
Why?
|
| Adenocarcinoma, Mucinous | 5 | 2017 | 523 | 0.810 |
Why?
|
| DNA Mutational Analysis | 29 | 2020 | 4114 | 0.770 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 18 | 2020 | 904 | 0.740 |
Why?
|
| Oligodendroglioma | 6 | 2019 | 274 | 0.730 |
Why?
|
| Genes, erbB-1 | 7 | 2017 | 161 | 0.730 |
Why?
|
| Glutarates | 7 | 2018 | 242 | 0.710 |
Why?
|
| Neoplasms | 22 | 2024 | 22350 | 0.710 |
Why?
|
| Gene Products, nef | 9 | 2000 | 101 | 0.690 |
Why?
|
| Neoplastic Cells, Circulating | 9 | 2023 | 949 | 0.610 |
Why?
|
| Humans | 292 | 2024 | 766766 | 0.590 |
Why?
|
| Receptors, Growth Factor | 4 | 2011 | 324 | 0.590 |
Why?
|
| Genetic Testing | 6 | 2019 | 3591 | 0.580 |
Why?
|
| Genomics | 6 | 2023 | 5923 | 0.570 |
Why?
|
| Aged, 80 and over | 69 | 2024 | 59550 | 0.550 |
Why?
|
| Quinazolines | 8 | 2016 | 1367 | 0.550 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2014 | 755 | 0.550 |
Why?
|
| Molecular Targeted Therapy | 15 | 2020 | 2823 | 0.540 |
Why?
|
| Biliary Tract Neoplasms | 2 | 2015 | 186 | 0.540 |
Why?
|
| Middle Aged | 137 | 2024 | 223257 | 0.540 |
Why?
|
| Receptor, trkA | 4 | 2019 | 159 | 0.530 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2020 | 705 | 0.520 |
Why?
|
| Mosaicism | 3 | 2021 | 480 | 0.520 |
Why?
|
| Chordoma | 3 | 2019 | 349 | 0.510 |
Why?
|
| Bile Ducts, Intrahepatic | 5 | 2023 | 303 | 0.510 |
Why?
|
| Molecular Diagnostic Techniques | 7 | 2019 | 614 | 0.500 |
Why?
|
| Female | 175 | 2024 | 396520 | 0.500 |
Why?
|
| Antineoplastic Agents | 25 | 2023 | 13643 | 0.500 |
Why?
|
| Immunohistochemistry | 30 | 2024 | 11061 | 0.500 |
Why?
|
| Simian immunodeficiency virus | 9 | 2000 | 812 | 0.490 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 5 | 2024 | 212 | 0.490 |
Why?
|
| Aged | 114 | 2024 | 171343 | 0.490 |
Why?
|
| Cytodiagnosis | 2 | 2016 | 450 | 0.490 |
Why?
|
| Adenocarcinoma, Clear Cell | 3 | 2021 | 218 | 0.490 |
Why?
|
| Neoplasm Recurrence, Local | 15 | 2022 | 9404 | 0.480 |
Why?
|
| Chromosomes, Human, Pair 19 | 3 | 2019 | 350 | 0.470 |
Why?
|
| Genes, ras | 5 | 2015 | 656 | 0.470 |
Why?
|
| Genotype | 26 | 2021 | 13036 | 0.470 |
Why?
|
| Gene Dosage | 7 | 2013 | 1211 | 0.470 |
Why?
|
| Lactams, Macrocyclic | 5 | 2018 | 319 | 0.460 |
Why?
|
| ras Proteins | 14 | 2015 | 1055 | 0.460 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 3 | 2009 | 82 | 0.450 |
Why?
|
| DNA, Neoplasm | 11 | 2019 | 1741 | 0.450 |
Why?
|
| Genes, Neoplasm | 3 | 2014 | 369 | 0.440 |
Why?
|
| Translocation, Genetic | 6 | 2022 | 1392 | 0.440 |
Why?
|
| Receptor, erbB-2 | 11 | 2024 | 2597 | 0.440 |
Why?
|
| Gallbladder Neoplasms | 2 | 2014 | 190 | 0.440 |
Why?
|
| Antibodies, Neutralizing | 6 | 2024 | 2010 | 0.440 |
Why?
|
| Adult | 104 | 2024 | 223307 | 0.440 |
Why?
|
| Chromosomes, Human, Pair 1 | 3 | 2019 | 640 | 0.440 |
Why?
|
| Phosphatidylinositol 3-Kinases | 14 | 2018 | 2881 | 0.430 |
Why?
|
| Male | 144 | 2024 | 364142 | 0.430 |
Why?
|
| Exons | 2 | 2016 | 2392 | 0.430 |
Why?
|
| DNA Copy Number Variations | 9 | 2024 | 2045 | 0.420 |
Why?
|
| Esophageal Neoplasms | 5 | 2020 | 1660 | 0.420 |
Why?
|
| Seroepidemiologic Studies | 4 | 2023 | 404 | 0.420 |
Why?
|
| Salivary Gland Neoplasms | 4 | 2024 | 306 | 0.420 |
Why?
|
| Breast Neoplasms | 16 | 2024 | 21162 | 0.410 |
Why?
|
| Cell Line, Tumor | 36 | 2021 | 17088 | 0.400 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 2 | 2011 | 367 | 0.400 |
Why?
|
| Chromosome Deletion | 5 | 2019 | 1384 | 0.390 |
Why?
|
| Chromosome Aberrations | 3 | 2018 | 1776 | 0.390 |
Why?
|
| Carcinoma, Squamous Cell | 5 | 2023 | 4049 | 0.390 |
Why?
|
| RNA-Binding Protein EWS | 4 | 2021 | 211 | 0.390 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 1217 | 0.380 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 12 | 2023 | 11872 | 0.380 |
Why?
|
| Comparative Genomic Hybridization | 5 | 2019 | 474 | 0.380 |
Why?
|
| Aneuploidy | 2 | 2019 | 573 | 0.380 |
Why?
|
| Wilms Tumor | 3 | 2013 | 378 | 0.380 |
Why?
|
| Genome, Human | 7 | 2021 | 4443 | 0.380 |
Why?
|
| Stomach Neoplasms | 4 | 2020 | 1474 | 0.370 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 3 | 2009 | 83 | 0.370 |
Why?
|
| Prognosis | 30 | 2024 | 29948 | 0.370 |
Why?
|
| DNA Methylation | 9 | 2021 | 4427 | 0.370 |
Why?
|
| Sequence Analysis, DNA | 11 | 2021 | 4780 | 0.360 |
Why?
|
| Pancreatic Neoplasms | 6 | 2015 | 5444 | 0.360 |
Why?
|
| Papillomavirus Infections | 5 | 2023 | 1639 | 0.360 |
Why?
|
| Tumor Suppressor Protein p53 | 12 | 2023 | 2948 | 0.350 |
Why?
|
| Receptor, EphB4 | 2 | 2015 | 39 | 0.350 |
Why?
|
| Genetic Variation | 7 | 2017 | 6612 | 0.350 |
Why?
|
| Polymerase Chain Reaction | 13 | 2021 | 6066 | 0.350 |
Why?
|
| Oncogene Fusion | 5 | 2019 | 84 | 0.350 |
Why?
|
| Odontogenic Tumors | 2 | 2021 | 48 | 0.340 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2015 | 454 | 0.340 |
Why?
|
| Liver Neoplasms | 9 | 2017 | 4353 | 0.340 |
Why?
|
| Gene Expression Regulation, Neoplastic | 17 | 2024 | 8621 | 0.340 |
Why?
|
| Carcinoma, Adenoid Cystic | 2 | 2024 | 262 | 0.330 |
Why?
|
| Melanoma | 4 | 2023 | 5700 | 0.320 |
Why?
|
| Carcinoma, Papillary | 3 | 2016 | 791 | 0.320 |
Why?
|
| Uterine Neoplasms | 3 | 2018 | 1424 | 0.320 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2014 | 1117 | 0.320 |
Why?
|
| Medical Informatics | 1 | 2016 | 744 | 0.320 |
Why?
|
| Receptor, trkC | 2 | 2019 | 63 | 0.320 |
Why?
|
| Pharmacogenetics | 1 | 2013 | 682 | 0.320 |
Why?
|
| Hydatidiform Mole | 1 | 2011 | 255 | 0.310 |
Why?
|
| Immunity, Humoral | 2 | 2024 | 608 | 0.310 |
Why?
|
| Chromosomes, Human, X | 2 | 2007 | 319 | 0.310 |
Why?
|
| Thyroid Neoplasms | 5 | 2024 | 2355 | 0.310 |
Why?
|
| Genetic Heterogeneity | 5 | 2019 | 735 | 0.300 |
Why?
|
| Rhabdomyosarcoma, Embryonal | 2 | 2022 | 99 | 0.290 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 4 | 2018 | 388 | 0.290 |
Why?
|
| Disease Progression | 16 | 2023 | 13640 | 0.290 |
Why?
|
| Chimera | 1 | 2009 | 455 | 0.290 |
Why?
|
| Gastrointestinal Neoplasms | 3 | 2020 | 957 | 0.280 |
Why?
|
| Gene Deletion | 3 | 2019 | 2669 | 0.280 |
Why?
|
| Neoplasm Staging | 15 | 2019 | 11218 | 0.280 |
Why?
|
| Proto-Oncogene Proteins c-ret | 2 | 2019 | 228 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2007 | 247 | 0.280 |
Why?
|
| Bile Ducts | 2 | 2020 | 288 | 0.270 |
Why?
|
| Acrylamides | 3 | 2018 | 260 | 0.270 |
Why?
|
| Oropharyngeal Neoplasms | 2 | 2023 | 492 | 0.270 |
Why?
|
| Tumor Suppressor Proteins | 6 | 2018 | 2801 | 0.270 |
Why?
|
| Skin Neoplasms | 3 | 2023 | 5861 | 0.270 |
Why?
|
| Microsatellite Instability | 6 | 2014 | 726 | 0.270 |
Why?
|
| Eosinophilia | 2 | 2022 | 554 | 0.260 |
Why?
|
| Dacarbazine | 4 | 2017 | 552 | 0.260 |
Why?
|
| Xenograft Model Antitumor Assays | 14 | 2020 | 3607 | 0.260 |
Why?
|
| Sequence Analysis, RNA | 4 | 2024 | 2039 | 0.250 |
Why?
|
| Immunoglobulin M | 5 | 2020 | 1527 | 0.250 |
Why?
|
| MAP Kinase Kinase 1 | 6 | 2017 | 330 | 0.250 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 4 | 2019 | 107 | 0.240 |
Why?
|
| Neoplasm Metastasis | 8 | 2020 | 4891 | 0.240 |
Why?
|
| Young Adult | 34 | 2024 | 59939 | 0.240 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2014 | 6512 | 0.230 |
Why?
|
| Carcinoma | 4 | 2023 | 2324 | 0.230 |
Why?
|
| Promoter Regions, Genetic | 7 | 2019 | 5789 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-myb | 1 | 2024 | 82 | 0.230 |
Why?
|
| Rhabdomyosarcoma | 2 | 2022 | 358 | 0.230 |
Why?
|
| Pyrimidines | 9 | 2020 | 3043 | 0.230 |
Why?
|
| Polymorphism, Genetic | 3 | 2011 | 4249 | 0.220 |
Why?
|
| Head and Neck Neoplasms | 3 | 2023 | 2929 | 0.220 |
Why?
|
| Pathology, Clinical | 2 | 2018 | 374 | 0.220 |
Why?
|
| Smad4 Protein | 4 | 2020 | 193 | 0.210 |
Why?
|
| Disease-Free Survival | 9 | 2018 | 6850 | 0.210 |
Why?
|
| Carcinoma in Situ | 3 | 2023 | 784 | 0.210 |
Why?
|
| Molecular Probes | 2 | 2019 | 309 | 0.210 |
Why?
|
| Colonic Neoplasms | 5 | 2018 | 2534 | 0.210 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2020 | 3804 | 0.200 |
Why?
|
| Vaccines, Synthetic | 2 | 2022 | 620 | 0.200 |
Why?
|
| Sensitivity and Specificity | 10 | 2024 | 14652 | 0.200 |
Why?
|
| Smoking | 7 | 2019 | 9077 | 0.200 |
Why?
|
| Software | 1 | 2016 | 4466 | 0.200 |
Why?
|
| Leukemia, Myeloid, Acute | 4 | 2022 | 3636 | 0.200 |
Why?
|
| Pancreatic Cyst | 2 | 2016 | 372 | 0.190 |
Why?
|
| Meningioma | 2 | 2022 | 1221 | 0.190 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 3 | 2017 | 85 | 0.190 |
Why?
|
| Pharmacy | 1 | 2023 | 92 | 0.190 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2022 | 91 | 0.190 |
Why?
|
| Meningeal Neoplasms | 2 | 2022 | 1255 | 0.190 |
Why?
|
| GTP Phosphohydrolases | 5 | 2016 | 525 | 0.190 |
Why?
|
| Benzimidazoles | 3 | 2019 | 862 | 0.180 |
Why?
|
| Retrospective Studies | 31 | 2024 | 81635 | 0.180 |
Why?
|
| Bone Cysts | 1 | 2021 | 48 | 0.180 |
Why?
|
| Retinoblastoma Binding Proteins | 2 | 2019 | 101 | 0.180 |
Why?
|
| Colorectal Neoplasms | 6 | 2018 | 6962 | 0.180 |
Why?
|
| Signal Transduction | 19 | 2020 | 23619 | 0.180 |
Why?
|
| Neoplasms, Muscle Tissue | 1 | 2021 | 68 | 0.180 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 746 | 0.180 |
Why?
|
| Nanopores | 1 | 2021 | 45 | 0.180 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2023 | 243 | 0.180 |
Why?
|
| Chromosomes, Artificial, Bacterial | 2 | 2019 | 125 | 0.180 |
Why?
|
| Craniopharyngioma | 1 | 2023 | 279 | 0.180 |
Why?
|
| Thoracic Neoplasms | 1 | 2023 | 269 | 0.180 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2017 | 614 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2016 | 996 | 0.170 |
Why?
|
| Cohort Studies | 18 | 2024 | 41710 | 0.170 |
Why?
|
| Survival Rate | 13 | 2020 | 12825 | 0.170 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 2023 | 289 | 0.170 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2019 | 2060 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2021 | 1405 | 0.170 |
Why?
|
| Immunologic Tests | 1 | 2020 | 101 | 0.170 |
Why?
|
| Estrogen Receptor alpha | 3 | 2019 | 581 | 0.170 |
Why?
|
| Remote Sensing Technology | 1 | 2021 | 93 | 0.170 |
Why?
|
| Adrenal Gland Neoplasms | 2 | 2015 | 732 | 0.170 |
Why?
|
| Delivery of Health Care | 2 | 2023 | 5368 | 0.170 |
Why?
|
| Blood Specimen Collection | 1 | 2021 | 238 | 0.170 |
Why?
|
| Cholangitis, Sclerosing | 1 | 2021 | 179 | 0.170 |
Why?
|
| Septins | 1 | 2019 | 47 | 0.160 |
Why?
|
| Chromogranins | 2 | 2017 | 160 | 0.160 |
Why?
|
| Astrocytoma | 4 | 2013 | 773 | 0.160 |
Why?
|
| MAP Kinase Signaling System | 2 | 2018 | 1491 | 0.160 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2015 | 1757 | 0.160 |
Why?
|
| Telomerase | 3 | 2018 | 750 | 0.160 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2020 | 183 | 0.160 |
Why?
|
| Mesothelioma | 1 | 2015 | 774 | 0.160 |
Why?
|
| Down-Regulation | 7 | 2000 | 2931 | 0.160 |
Why?
|
| DNA-Binding Proteins | 9 | 2022 | 9611 | 0.160 |
Why?
|
| Alphapapillomavirus | 1 | 2022 | 219 | 0.160 |
Why?
|
| RNA Helicases | 1 | 2020 | 144 | 0.160 |
Why?
|
| Genital Neoplasms, Female | 2 | 2017 | 534 | 0.160 |
Why?
|
| Humerus | 1 | 2021 | 273 | 0.160 |
Why?
|
| Base Sequence | 8 | 2015 | 12415 | 0.160 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2018 | 20 | 0.160 |
Why?
|
| NFATC Transcription Factors | 1 | 2021 | 392 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-akt | 5 | 2019 | 2456 | 0.160 |
Why?
|
| Jaw Neoplasms | 1 | 2019 | 71 | 0.160 |
Why?
|
| Receptor, trkB | 1 | 2019 | 123 | 0.160 |
Why?
|
| Homeodomain Proteins | 3 | 2024 | 2430 | 0.160 |
Why?
|
| Genes, erbB-2 | 3 | 2017 | 161 | 0.150 |
Why?
|
| Immunoglobulin G | 5 | 2020 | 4559 | 0.150 |
Why?
|
| Reproducibility of Results | 8 | 2019 | 20144 | 0.150 |
Why?
|
| Fibula | 1 | 2021 | 270 | 0.150 |
Why?
|
| Antibody Specificity | 1 | 2020 | 1062 | 0.150 |
Why?
|
| Virion | 1 | 2000 | 428 | 0.150 |
Why?
|
| Thrombocytosis | 1 | 2018 | 88 | 0.150 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 2 | 2017 | 194 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2019 | 313 | 0.150 |
Why?
|
| Cyst Fluid | 2 | 2016 | 86 | 0.150 |
Why?
|
| Mandibular Neoplasms | 1 | 2019 | 131 | 0.150 |
Why?
|
| Neuregulin-1 | 2 | 2017 | 136 | 0.150 |
Why?
|
| Cyanides | 1 | 2018 | 82 | 0.150 |
Why?
|
| Adaptor Proteins, Signal Transducing | 4 | 2014 | 2902 | 0.150 |
Why?
|
| Enzyme Inhibitors | 3 | 2018 | 3721 | 0.150 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 352 | 0.150 |
Why?
|
| Fingers | 1 | 2021 | 508 | 0.150 |
Why?
|
| Transcription Factors | 9 | 2022 | 12150 | 0.150 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2018 | 117 | 0.150 |
Why?
|
| Color | 1 | 2019 | 297 | 0.150 |
Why?
|
| BRCA1 Protein | 2 | 2024 | 1155 | 0.150 |
Why?
|
| Parotid Neoplasms | 1 | 2019 | 158 | 0.150 |
Why?
|
| NAD | 3 | 2017 | 617 | 0.150 |
Why?
|
| Gene Expression Profiling | 9 | 2017 | 9525 | 0.150 |
Why?
|
| Treatment Outcome | 18 | 2020 | 65273 | 0.140 |
Why?
|
| Drug Screening Assays, Antitumor | 4 | 2014 | 718 | 0.140 |
Why?
|
| Guanidines | 1 | 2018 | 194 | 0.140 |
Why?
|
| Adenofibroma | 1 | 2017 | 25 | 0.140 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2021 | 827 | 0.140 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2020 | 409 | 0.140 |
Why?
|
| Cytogenetic Analysis | 4 | 2018 | 270 | 0.140 |
Why?
|
| Phenylurea Compounds | 2 | 2019 | 533 | 0.140 |
Why?
|
| Carbazoles | 2 | 2019 | 230 | 0.140 |
Why?
|
| Dystrophin | 1 | 2018 | 283 | 0.140 |
Why?
|
| Neuroectodermal Tumors, Primitive, Peripheral | 1 | 2017 | 43 | 0.140 |
Why?
|
| Transcription Factors, TFII | 1 | 1997 | 62 | 0.140 |
Why?
|
| Barrett Esophagus | 2 | 2011 | 494 | 0.140 |
Why?
|
| Immunoassay | 1 | 2020 | 742 | 0.140 |
Why?
|
| Magnetic Resonance Spectroscopy | 2 | 2018 | 3681 | 0.140 |
Why?
|
| Central Nervous System Neoplasms | 3 | 2017 | 926 | 0.140 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2020 | 627 | 0.140 |
Why?
|
| Viral Vaccines | 1 | 2022 | 596 | 0.130 |
Why?
|
| Codon | 3 | 2014 | 599 | 0.130 |
Why?
|
| Cystadenoma, Mucinous | 1 | 2016 | 62 | 0.130 |
Why?
|
| Leiomyoma | 1 | 2021 | 644 | 0.130 |
Why?
|
| Bone Neoplasms | 2 | 2021 | 2561 | 0.130 |
Why?
|
| Diagnostic Tests, Routine | 2 | 2020 | 789 | 0.130 |
Why?
|
| Neoplastic Stem Cells | 4 | 2017 | 1351 | 0.130 |
Why?
|
| Fibrosarcoma | 1 | 2018 | 313 | 0.130 |
Why?
|
| Karyotyping | 2 | 2009 | 1176 | 0.130 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2024 | 949 | 0.130 |
Why?
|
| Specimen Handling | 1 | 2021 | 706 | 0.130 |
Why?
|
| Piperidines | 4 | 2020 | 1663 | 0.130 |
Why?
|
| HIV-1 | 7 | 2000 | 6948 | 0.130 |
Why?
|
| src Homology Domains | 4 | 2007 | 361 | 0.130 |
Why?
|
| Vesicle-Associated Membrane Protein 2 | 1 | 2015 | 17 | 0.130 |
Why?
|
| Cell Proliferation | 9 | 2020 | 10445 | 0.130 |
Why?
|
| Mice, SCID | 5 | 2019 | 2628 | 0.130 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2019 | 343 | 0.130 |
Why?
|
| Point Mutation | 4 | 2016 | 1591 | 0.120 |
Why?
|
| Aniline Compounds | 2 | 2018 | 1079 | 0.120 |
Why?
|
| Phosphoproteins | 3 | 2018 | 2448 | 0.120 |
Why?
|
| beta Catenin | 4 | 2014 | 1048 | 0.120 |
Why?
|
| BRCA2 Protein | 1 | 2020 | 802 | 0.120 |
Why?
|
| nef Gene Products, Human Immunodeficiency Virus | 7 | 2000 | 149 | 0.120 |
Why?
|
| Lectins, C-Type | 2 | 2015 | 592 | 0.120 |
Why?
|
| Tropomyosin | 1 | 2015 | 105 | 0.120 |
Why?
|
| High-Throughput Screening Assays | 1 | 2021 | 938 | 0.120 |
Why?
|
| RNA, Small Interfering | 7 | 2020 | 3425 | 0.120 |
Why?
|
| Genes, nef | 3 | 2000 | 52 | 0.120 |
Why?
|
| Biliary Tract | 1 | 2015 | 136 | 0.120 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2015 | 1404 | 0.120 |
Why?
|
| Massachusetts | 4 | 2020 | 8891 | 0.120 |
Why?
|
| Antigens, Differentiation, B-Lymphocyte | 1 | 2015 | 318 | 0.120 |
Why?
|
| Prospective Studies | 17 | 2022 | 54871 | 0.120 |
Why?
|
| Workflow | 2 | 2017 | 859 | 0.120 |
Why?
|
| Pituitary Neoplasms | 1 | 2023 | 1324 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2018 | 1105 | 0.120 |
Why?
|
| Administration, Oral | 2 | 2014 | 4018 | 0.120 |
Why?
|
| False Negative Reactions | 1 | 2015 | 570 | 0.120 |
Why?
|
| DNA Helicases | 1 | 2020 | 853 | 0.120 |
Why?
|
| Femur | 1 | 2021 | 1318 | 0.120 |
Why?
|
| Esophagogastric Junction | 2 | 2020 | 350 | 0.120 |
Why?
|
| Mice | 22 | 2020 | 81889 | 0.110 |
Why?
|
| Neoplasm Proteins | 3 | 2018 | 3601 | 0.110 |
Why?
|
| Cecal Neoplasms | 1 | 2014 | 27 | 0.110 |
Why?
|
| Gene Expression | 8 | 2018 | 7585 | 0.110 |
Why?
|
| Liver Circulation | 1 | 2014 | 163 | 0.110 |
Why?
|
| Tumor Cells, Cultured | 6 | 2020 | 6104 | 0.110 |
Why?
|
| Benzoquinones | 2 | 2014 | 198 | 0.110 |
Why?
|
| Leiomyosarcoma | 1 | 2018 | 426 | 0.110 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 2014 | 60 | 0.110 |
Why?
|
| Phenotype | 14 | 2019 | 16724 | 0.110 |
Why?
|
| Pathology, Molecular | 2 | 2014 | 329 | 0.110 |
Why?
|
| Animals | 35 | 2024 | 168930 | 0.110 |
Why?
|
| Indazoles | 1 | 2015 | 306 | 0.110 |
Why?
|
| Molecular Sequence Data | 12 | 2015 | 17608 | 0.110 |
Why?
|
| Kidney Neoplasms | 2 | 2007 | 4282 | 0.110 |
Why?
|
| Nuclear Proteins | 5 | 2022 | 5795 | 0.110 |
Why?
|
| Papillomaviridae | 4 | 2023 | 1139 | 0.110 |
Why?
|
| Adenocarcinoma, Papillary | 2 | 2012 | 86 | 0.110 |
Why?
|
| Medical Oncology | 3 | 2023 | 2340 | 0.110 |
Why?
|
| Adolescent | 19 | 2023 | 88904 | 0.110 |
Why?
|
| Hemangiosarcoma | 1 | 2015 | 214 | 0.110 |
Why?
|
| Receptors, Estrogen | 4 | 2024 | 2251 | 0.110 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2013 | 42 | 0.110 |
Why?
|
| Aminopyridines | 4 | 2018 | 577 | 0.110 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2015 | 195 | 0.110 |
Why?
|
| Hepatoblastoma | 1 | 2013 | 90 | 0.110 |
Why?
|
| DNA, Mitochondrial | 1 | 2018 | 872 | 0.100 |
Why?
|
| Biopsy | 7 | 2020 | 6779 | 0.100 |
Why?
|
| Adenosine Triphosphate | 1 | 2019 | 2001 | 0.100 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3110 | 0.100 |
Why?
|
| Mice, Nude | 5 | 2020 | 3616 | 0.100 |
Why?
|
| Apocrine Glands | 1 | 2012 | 31 | 0.100 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2020 | 4570 | 0.100 |
Why?
|
| Cholangiopancreatography, Endoscopic Retrograde | 1 | 2015 | 520 | 0.100 |
Why?
|
| Histocompatibility Antigens Class I | 7 | 2000 | 1362 | 0.100 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3232 | 0.100 |
Why?
|
| Oncogenes | 3 | 2014 | 1231 | 0.100 |
Why?
|
| Lung | 3 | 2018 | 10067 | 0.100 |
Why?
|
| Myeloproliferative Disorders | 1 | 2018 | 616 | 0.100 |
Why?
|
| Eccrine Glands | 1 | 2012 | 52 | 0.100 |
Why?
|
| Carcinoma, Ductal | 1 | 2012 | 96 | 0.100 |
Why?
|
| Blotting, Western | 6 | 2017 | 5022 | 0.100 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2013 | 125 | 0.100 |
Why?
|
| Follow-Up Studies | 12 | 2020 | 39309 | 0.100 |
Why?
|
| Single-Cell Analysis | 3 | 2022 | 2534 | 0.100 |
Why?
|
| DNA Repair Enzymes | 4 | 2018 | 342 | 0.100 |
Why?
|
| Bone Marrow Transplantation | 2 | 2011 | 2730 | 0.100 |
Why?
|
| Lactams | 3 | 2018 | 159 | 0.100 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2019 | 1899 | 0.100 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2014 | 422 | 0.100 |
Why?
|
| Transforming Growth Factor beta1 | 2 | 2013 | 637 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 3 | 2015 | 3609 | 0.100 |
Why?
|
| Oncolytic Virotherapy | 1 | 2017 | 520 | 0.100 |
Why?
|
| Nucleic Acid Hybridization | 3 | 2007 | 1305 | 0.090 |
Why?
|
| Pulmonary Circulation | 1 | 2014 | 744 | 0.090 |
Why?
|
| Databases, Genetic | 2 | 2019 | 1756 | 0.090 |
Why?
|
| Caveolin 1 | 1 | 2013 | 255 | 0.090 |
Why?
|
| Capillary Leak Syndrome | 1 | 2011 | 34 | 0.090 |
Why?
|
| Retinoblastoma Protein | 1 | 2015 | 670 | 0.090 |
Why?
|
| Survival Analysis | 7 | 2020 | 10100 | 0.090 |
Why?
|
| Graft Survival | 2 | 2015 | 3904 | 0.090 |
Why?
|
| Regression Analysis | 1 | 2020 | 6329 | 0.090 |
Why?
|
| Membrane Proteins | 8 | 2016 | 7868 | 0.090 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2015 | 1442 | 0.090 |
Why?
|
| DNA, Satellite | 1 | 2011 | 67 | 0.090 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2021 | 1434 | 0.090 |
Why?
|
| Diagnosis, Differential | 6 | 2018 | 12985 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 6 | 2015 | 9244 | 0.090 |
Why?
|
| Fluorescent Dyes | 1 | 2019 | 1927 | 0.090 |
Why?
|
| Multivariate Analysis | 3 | 2020 | 12064 | 0.090 |
Why?
|
| Amino Acid Sequence | 9 | 2015 | 13411 | 0.090 |
Why?
|
| Reimbursement Mechanisms | 1 | 2016 | 670 | 0.090 |
Why?
|
| Drug Resistance | 2 | 2014 | 1592 | 0.090 |
Why?
|
| Deoxycytidine | 2 | 2014 | 886 | 0.090 |
Why?
|
| Radiography | 3 | 2011 | 6968 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2023 | 635 | 0.090 |
Why?
|
| DNA Mismatch Repair | 2 | 2014 | 432 | 0.090 |
Why?
|
| Pulmonary Fibrosis | 1 | 2014 | 505 | 0.090 |
Why?
|
| DNA Probes | 1 | 2011 | 541 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2011 | 310 | 0.090 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2014 | 605 | 0.090 |
Why?
|
| Carcinosarcoma | 1 | 2010 | 108 | 0.080 |
Why?
|
| Gliosis | 1 | 2011 | 246 | 0.080 |
Why?
|
| Benzamides | 1 | 2015 | 1375 | 0.080 |
Why?
|
| Virus Replication | 5 | 2000 | 2457 | 0.080 |
Why?
|
| Stress, Physiological | 1 | 2017 | 1406 | 0.080 |
Why?
|
| Sequence Deletion | 3 | 2013 | 1494 | 0.080 |
Why?
|
| Tumor Burden | 4 | 2017 | 1900 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 1996 | 0.080 |
Why?
|
| Radiology | 1 | 2023 | 2105 | 0.080 |
Why?
|
| Leukemia, Myeloid | 1 | 2012 | 695 | 0.080 |
Why?
|
| Sweat Gland Neoplasms | 1 | 2011 | 111 | 0.080 |
Why?
|
| Piperazines | 4 | 2021 | 2547 | 0.080 |
Why?
|
| Cerebellar Neoplasms | 1 | 2014 | 588 | 0.080 |
Why?
|
| Germinal Center | 1 | 2011 | 379 | 0.080 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2014 | 723 | 0.080 |
Why?
|
| DNA Modification Methylases | 3 | 2018 | 207 | 0.080 |
Why?
|
| Sulfones | 3 | 2016 | 447 | 0.080 |
Why?
|
| Cell Adhesion Molecules | 1 | 2015 | 1612 | 0.080 |
Why?
|
| Pancreas | 1 | 2015 | 1698 | 0.080 |
Why?
|
| Medulloblastoma | 1 | 2014 | 679 | 0.080 |
Why?
|
| Molecular Biology | 1 | 2012 | 573 | 0.080 |
Why?
|
| Membrane Glycoproteins | 1 | 2019 | 3702 | 0.080 |
Why?
|
| Endometrial Neoplasms | 1 | 2018 | 1380 | 0.080 |
Why?
|
| Cross Reactions | 2 | 2020 | 826 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2019 | 2978 | 0.080 |
Why?
|
| Eligibility Determination | 1 | 2012 | 421 | 0.080 |
Why?
|
| Algorithms | 2 | 2019 | 14072 | 0.080 |
Why?
|
| Aspirin | 1 | 2020 | 3135 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2023 | 562 | 0.080 |
Why?
|
| Referral and Consultation | 2 | 2023 | 3618 | 0.080 |
Why?
|
| Adenomatous Polyps | 1 | 2009 | 109 | 0.070 |
Why?
|
| RNA, Neoplasm | 1 | 2011 | 747 | 0.070 |
Why?
|
| Carboplatin | 1 | 2011 | 789 | 0.070 |
Why?
|
| Lymphoma, Follicular | 1 | 2012 | 460 | 0.070 |
Why?
|
| Kidney Transplantation | 2 | 2015 | 4278 | 0.070 |
Why?
|
| Drug Monitoring | 2 | 2018 | 962 | 0.070 |
Why?
|
| Phosphorylation | 7 | 2015 | 8307 | 0.070 |
Why?
|
| Radiosurgery | 1 | 2017 | 1329 | 0.070 |
Why?
|
| Drug Interactions | 1 | 2012 | 1419 | 0.070 |
Why?
|
| Research | 1 | 2016 | 1977 | 0.070 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1997 | 2571 | 0.070 |
Why?
|
| Sex Cord-Gonadal Stromal Tumors | 1 | 2009 | 117 | 0.070 |
Why?
|
| Genes, p16 | 2 | 2020 | 157 | 0.070 |
Why?
|
| T-Lymphocytes | 4 | 2021 | 10264 | 0.070 |
Why?
|
| Gene Frequency | 4 | 2015 | 3624 | 0.070 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2012 | 329 | 0.070 |
Why?
|
| Pneumonectomy | 1 | 2014 | 1147 | 0.070 |
Why?
|
| Advisory Committees | 1 | 2011 | 797 | 0.070 |
Why?
|
| Tumor Microenvironment | 2 | 2018 | 3944 | 0.070 |
Why?
|
| RNA, Untranslated | 1 | 2011 | 455 | 0.070 |
Why?
|
| Founder Effect | 1 | 2007 | 185 | 0.070 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2007 | 112 | 0.070 |
Why?
|
| Vision Disorders | 1 | 2014 | 1090 | 0.070 |
Why?
|
| Calmodulin-Binding Proteins | 2 | 2019 | 238 | 0.070 |
Why?
|
| Bone Marrow | 2 | 2014 | 2926 | 0.070 |
Why?
|
| Sarcoma | 1 | 2018 | 1802 | 0.070 |
Why?
|
| Immunoglobulin A | 2 | 2020 | 992 | 0.070 |
Why?
|
| Venous Thromboembolism | 1 | 2020 | 1882 | 0.070 |
Why?
|
| Genes, Wilms Tumor | 1 | 2007 | 92 | 0.070 |
Why?
|
| DNA Primers | 3 | 2021 | 2826 | 0.070 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2020 | 638 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 1 | 2014 | 1061 | 0.070 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2007 | 1481 | 0.070 |
Why?
|
| Spheroids, Cellular | 2 | 2020 | 328 | 0.070 |
Why?
|
| Fractures, Compression | 1 | 2008 | 132 | 0.070 |
Why?
|
| Pandemics | 3 | 2021 | 8735 | 0.070 |
Why?
|
| Mesoderm | 1 | 2009 | 679 | 0.070 |
Why?
|
| RNA, Messenger | 3 | 2018 | 12791 | 0.070 |
Why?
|
| Budd-Chiari Syndrome | 1 | 2006 | 24 | 0.070 |
Why?
|
| Brain | 4 | 2021 | 27159 | 0.070 |
Why?
|
| Autopsy | 3 | 2019 | 1011 | 0.070 |
Why?
|
| Polymorphism, Single Nucleotide | 6 | 2019 | 16044 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2019 | 20708 | 0.070 |
Why?
|
| Child | 11 | 2022 | 80668 | 0.060 |
Why?
|
| Thrombosis | 1 | 2020 | 2953 | 0.060 |
Why?
|
| Zinc Fingers | 1 | 2008 | 577 | 0.060 |
Why?
|
| Telemedicine | 1 | 2023 | 3111 | 0.060 |
Why?
|
| Vulvar Neoplasms | 1 | 2008 | 266 | 0.060 |
Why?
|
| Colonoscopy | 1 | 2014 | 1409 | 0.060 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2018 | 200 | 0.060 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 2815 | 0.060 |
Why?
|
| Time Factors | 9 | 2024 | 40149 | 0.060 |
Why?
|
| Endonucleases | 1 | 2008 | 371 | 0.060 |
Why?
|
| HEK293 Cells | 3 | 2021 | 4276 | 0.060 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 2 | 2000 | 543 | 0.060 |
Why?
|
| DNA, Viral | 2 | 2023 | 2201 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 2 | 2015 | 3757 | 0.060 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 4 | 2000 | 301 | 0.060 |
Why?
|
| Serine Endopeptidases | 1 | 2010 | 1027 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2010 | 1071 | 0.060 |
Why?
|
| Adaptor Protein Complex alpha Subunits | 3 | 2000 | 23 | 0.060 |
Why?
|
| Deglutition Disorders | 1 | 2011 | 640 | 0.060 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2014 | 939 | 0.060 |
Why?
|
| Tyrosine | 5 | 2000 | 1425 | 0.060 |
Why?
|
| Cytokines | 2 | 2020 | 7438 | 0.060 |
Why?
|
| Superoxide Dismutase | 1 | 2007 | 595 | 0.060 |
Why?
|
| Lymphoma, B-Cell | 1 | 2011 | 945 | 0.060 |
Why?
|
| Rectal Neoplasms | 1 | 2014 | 1183 | 0.060 |
Why?
|
| Hyperplasia | 2 | 2023 | 1150 | 0.060 |
Why?
|
| Computational Biology | 3 | 2019 | 3564 | 0.060 |
Why?
|
| Genes, Duplicate | 1 | 2004 | 31 | 0.060 |
Why?
|
| Carcinoembryonic Antigen | 2 | 2016 | 337 | 0.060 |
Why?
|
| Cost-Benefit Analysis | 1 | 2017 | 5536 | 0.060 |
Why?
|
| Back Pain | 1 | 2008 | 547 | 0.060 |
Why?
|
| Glucose | 1 | 2016 | 4340 | 0.060 |
Why?
|
| Enzyme Activation | 3 | 2015 | 3587 | 0.060 |
Why?
|
| Jurkat Cells | 4 | 1999 | 740 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2018 | 18075 | 0.060 |
Why?
|
| Cell Survival | 4 | 2016 | 5748 | 0.060 |
Why?
|
| Sirolimus | 1 | 2011 | 1540 | 0.060 |
Why?
|
| COS Cells | 4 | 2000 | 1135 | 0.060 |
Why?
|
| Cell Cycle Proteins | 2 | 2016 | 3439 | 0.060 |
Why?
|
| Fatal Outcome | 3 | 2015 | 1838 | 0.060 |
Why?
|
| Receptors, Fibroblast Growth Factor | 1 | 2024 | 193 | 0.060 |
Why?
|
| Epigenesis, Genetic | 2 | 2019 | 3824 | 0.060 |
Why?
|
| Dendritic Cells | 1 | 2015 | 2747 | 0.060 |
Why?
|
| Thoracic Vertebrae | 1 | 2008 | 613 | 0.050 |
Why?
|
| Cell Lineage | 2 | 2017 | 2572 | 0.050 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 2057 | 0.050 |
Why?
|
| Viral Load | 3 | 2022 | 3385 | 0.050 |
Why?
|
| Cytoskeletal Proteins | 2 | 2019 | 1325 | 0.050 |
Why?
|
| Amino Acid Substitution | 2 | 2014 | 1742 | 0.050 |
Why?
|
| Crohn Disease | 1 | 2016 | 2286 | 0.050 |
Why?
|
| Quinazolinones | 2 | 2019 | 219 | 0.050 |
Why?
|
| Adenoma | 1 | 2014 | 2155 | 0.050 |
Why?
|
| RNA Editing | 2 | 2014 | 149 | 0.050 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 2008 | 747 | 0.050 |
Why?
|
| Macaca mulatta | 5 | 2000 | 2341 | 0.050 |
Why?
|
| Sequence Alignment | 2 | 2015 | 2177 | 0.050 |
Why?
|
| Estrogen Antagonists | 1 | 2023 | 151 | 0.050 |
Why?
|
| Molecular Sequence Annotation | 1 | 2015 | 526 | 0.050 |
Why?
|
| Pyrroles | 1 | 2009 | 1121 | 0.050 |
Why?
|
| Oligodendroglia | 1 | 2006 | 539 | 0.050 |
Why?
|
| K562 Cells | 2 | 2018 | 645 | 0.050 |
Why?
|
| Genetic Engineering | 1 | 2008 | 936 | 0.050 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2007 | 606 | 0.050 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2007 | 3796 | 0.050 |
Why?
|
| Genetic Linkage | 1 | 2007 | 2342 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 2 | 2015 | 329 | 0.050 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2022 | 183 | 0.050 |
Why?
|
| Islets of Langerhans | 1 | 2008 | 1350 | 0.050 |
Why?
|
| Oxygen | 1 | 2013 | 4251 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2014 | 464 | 0.050 |
Why?
|
| Spinal Fractures | 1 | 2008 | 702 | 0.050 |
Why?
|
| Positron-Emission Tomography | 3 | 2015 | 6550 | 0.050 |
Why?
|
| Cell Nucleus | 3 | 2020 | 2870 | 0.050 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2021 | 167 | 0.050 |
Why?
|
| Cell Movement | 3 | 2015 | 5199 | 0.050 |
Why?
|
| Kidney | 2 | 2015 | 7074 | 0.050 |
Why?
|
| Predictive Value of Tests | 6 | 2018 | 15416 | 0.050 |
Why?
|
| Disease Models, Animal | 4 | 2023 | 18330 | 0.050 |
Why?
|
| Biology | 1 | 2023 | 292 | 0.050 |
Why?
|
| Immune Evasion | 1 | 2024 | 375 | 0.050 |
Why?
|
| Structure-Activity Relationship | 2 | 2019 | 3053 | 0.050 |
Why?
|
| Indoles | 1 | 2009 | 1834 | 0.040 |
Why?
|
| Lymph Nodes | 1 | 2012 | 3468 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2015 | 5386 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 382 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2021 | 190 | 0.040 |
Why?
|
| Electroporation | 1 | 2021 | 238 | 0.040 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 4853 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2007 | 1504 | 0.040 |
Why?
|
| Protein Conformation | 3 | 2014 | 3947 | 0.040 |
Why?
|
| Proportional Hazards Models | 5 | 2014 | 12534 | 0.040 |
Why?
|
| Salivary Glands | 1 | 2021 | 231 | 0.040 |
Why?
|
| Databases, Factual | 1 | 2016 | 8066 | 0.040 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2020 | 101 | 0.040 |
Why?
|
| Sex Factors | 2 | 2015 | 10619 | 0.040 |
Why?
|
| Child, Preschool | 6 | 2021 | 42577 | 0.040 |
Why?
|
| Neuroblastoma | 1 | 2008 | 1266 | 0.040 |
Why?
|
| Immunophenotyping | 2 | 2016 | 1867 | 0.040 |
Why?
|
| Chromatography, Affinity | 1 | 2020 | 524 | 0.040 |
Why?
|
| Mutation, Missense | 3 | 2018 | 2590 | 0.040 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 372 | 0.040 |
Why?
|
| HIV Long-Term Survivors | 1 | 2000 | 140 | 0.040 |
Why?
|
| Mammary Glands, Animal | 1 | 2020 | 273 | 0.040 |
Why?
|
| Metabolomics | 2 | 2020 | 1675 | 0.040 |
Why?
|
| Sex Chromatin | 1 | 2018 | 19 | 0.040 |
Why?
|
| Lymphoma | 1 | 2008 | 1900 | 0.040 |
Why?
|
| Graft Rejection | 2 | 2011 | 4504 | 0.040 |
Why?
|
| Pyridazines | 1 | 2020 | 199 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 1946 | 0.040 |
Why?
|
| Genes, myc | 1 | 2020 | 391 | 0.040 |
Why?
|
| Astrocytes | 1 | 2006 | 1351 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2023 | 4652 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2019 | 176 | 0.040 |
Why?
|
| Biotechnology | 1 | 2020 | 283 | 0.040 |
Why?
|
| Ethylnitrosourea | 1 | 2018 | 50 | 0.040 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2011 | 2326 | 0.040 |
Why?
|
| Coronavirus | 1 | 2020 | 155 | 0.040 |
Why?
|
| Calcitonin | 1 | 2019 | 327 | 0.040 |
Why?
|
| Haploidy | 1 | 2018 | 128 | 0.040 |
Why?
|
| Cell Differentiation | 3 | 2016 | 11651 | 0.040 |
Why?
|
| Pyridones | 2 | 2017 | 818 | 0.040 |
Why?
|
| Cell Hypoxia | 1 | 2020 | 661 | 0.040 |
Why?
|
| Immunoblotting | 2 | 2012 | 1647 | 0.040 |
Why?
|
| Stereotaxic Techniques | 1 | 2020 | 551 | 0.040 |
Why?
|
| Mitotic Index | 1 | 2018 | 160 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 2021 | 1103 | 0.040 |
Why?
|
| Genes, p53 | 1 | 2020 | 711 | 0.040 |
Why?
|
| United States | 2 | 2024 | 72951 | 0.040 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2011 | 615 | 0.040 |
Why?
|
| Epithelial Cells | 1 | 2009 | 3691 | 0.040 |
Why?
|
| Chromosomes, Human | 1 | 2019 | 437 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2012 | 723 | 0.040 |
Why?
|
| Antigens, Viral | 1 | 2022 | 995 | 0.040 |
Why?
|
| Phthalazines | 1 | 2020 | 397 | 0.040 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2017 | 203 | 0.040 |
Why?
|
| Remission Induction | 1 | 2023 | 2413 | 0.040 |
Why?
|
| Capillaries | 1 | 2020 | 755 | 0.040 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2009 | 432 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2017 | 205 | 0.040 |
Why?
|
| Transcription Factor TFIIIA | 1 | 2016 | 24 | 0.040 |
Why?
|
| Treatment Failure | 2 | 2017 | 2659 | 0.040 |
Why?
|
| Transcription Factor TFIIH | 1 | 1997 | 33 | 0.030 |
Why?
|
| Risk Factors | 7 | 2023 | 74881 | 0.030 |
Why?
|
| Receptors, Steroid | 1 | 2017 | 157 | 0.030 |
Why?
|
| Binding Sites | 4 | 2015 | 6012 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2017 | 166 | 0.030 |
Why?
|
| E2F Transcription Factors | 1 | 2017 | 270 | 0.030 |
Why?
|
| Virulence | 1 | 2000 | 1294 | 0.030 |
Why?
|
| Clinical Trials as Topic | 4 | 2017 | 8045 | 0.030 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 1999 | 434 | 0.030 |
Why?
|
| Cell Line | 3 | 2020 | 15563 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2018 | 684 | 0.030 |
Why?
|
| Plasmids | 1 | 2021 | 2268 | 0.030 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2018 | 429 | 0.030 |
Why?
|
| Immunocompromised Host | 1 | 2022 | 865 | 0.030 |
Why?
|
| Veins | 1 | 2020 | 769 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 895 | 0.030 |
Why?
|
| Epitopes | 1 | 2022 | 2526 | 0.030 |
Why?
|
| Pentosyltransferases | 1 | 2015 | 62 | 0.030 |
Why?
|
| Osteoblasts | 1 | 2021 | 1144 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2014 | 10745 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2006 | 3450 | 0.030 |
Why?
|
| HLA Antigens | 1 | 2021 | 1339 | 0.030 |
Why?
|
| Age Factors | 2 | 2009 | 18397 | 0.030 |
Why?
|
| Transfection | 2 | 2015 | 5754 | 0.030 |
Why?
|
| Alleles | 4 | 2015 | 6895 | 0.030 |
Why?
|
| Cystadenoma | 1 | 2015 | 76 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2020 | 1159 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2017 | 385 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2017 | 454 | 0.030 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2017 | 296 | 0.030 |
Why?
|
| Oncogene Protein p21(ras) | 1 | 2015 | 69 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2019 | 2275 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1997 | 897 | 0.030 |
Why?
|
| Technetium Tc 99m Aggregated Albumin | 1 | 2014 | 68 | 0.030 |
Why?
|
| Colon, Ascending | 1 | 2014 | 14 | 0.030 |
Why?
|
| Breast | 1 | 2023 | 1971 | 0.030 |
Why?
|
| Database Management Systems | 1 | 2016 | 263 | 0.030 |
Why?
|
| Purines | 1 | 2018 | 615 | 0.030 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2014 | 147 | 0.030 |
Why?
|
| RNA Interference | 2 | 2016 | 2827 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 1999 | 1206 | 0.030 |
Why?
|
| Apoptosis | 3 | 2016 | 9513 | 0.030 |
Why?
|
| Nephritis | 1 | 2015 | 146 | 0.030 |
Why?
|
| Kinetics | 1 | 2022 | 6287 | 0.030 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 4 | 1 | 2013 | 17 | 0.030 |
Why?
|
| Fibroblast Growth Factor 3 | 1 | 2013 | 17 | 0.030 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2018 | 878 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2016 | 564 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2019 | 1787 | 0.030 |
Why?
|
| Quality Control | 1 | 2017 | 834 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2017 | 949 | 0.030 |
Why?
|
| Drug Delivery Systems | 2 | 2018 | 2210 | 0.030 |
Why?
|
| Simplexvirus | 1 | 2017 | 805 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 2016 | 784 | 0.030 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2015 | 304 | 0.030 |
Why?
|
| Hyperphosphatemia | 1 | 2013 | 38 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2014 | 303 | 0.030 |
Why?
|
| Liver Failure | 1 | 2015 | 252 | 0.030 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 14762 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2008 | 3446 | 0.030 |
Why?
|
| Pancreatic Ducts | 1 | 2015 | 330 | 0.030 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2018 | 4047 | 0.030 |
Why?
|
| Proto-Oncogenes | 1 | 2014 | 321 | 0.030 |
Why?
|
| Receptor, Notch1 | 1 | 2016 | 518 | 0.030 |
Why?
|
| Hepatectomy | 1 | 2017 | 589 | 0.030 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2014 | 355 | 0.030 |
Why?
|
| bcl-X Protein | 1 | 2015 | 412 | 0.030 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2014 | 705 | 0.030 |
Why?
|
| Nerve Tissue Proteins | 2 | 2012 | 4400 | 0.030 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2014 | 182 | 0.030 |
Why?
|
| ROC Curve | 1 | 2021 | 3620 | 0.030 |
Why?
|
| Idarubicin | 1 | 2012 | 59 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2019 | 1363 | 0.030 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2012 | 49 | 0.030 |
Why?
|
| Random Allocation | 1 | 2017 | 2394 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2014 | 406 | 0.030 |
Why?
|
| Trans-Activators | 1 | 2022 | 2855 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 505 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 594 | 0.020 |
Why?
|
| Glycolysis | 1 | 2016 | 838 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2017 | 1012 | 0.020 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2012 | 80 | 0.020 |
Why?
|
| Protein Binding | 3 | 2017 | 9320 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2015 | 2551 | 0.020 |
Why?
|
| Infant, Newborn | 2 | 2012 | 26389 | 0.020 |
Why?
|
| GTP-Binding Protein alpha Subunits | 1 | 2012 | 103 | 0.020 |
Why?
|
| World Health Organization | 1 | 2017 | 1327 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2015 | 1882 | 0.020 |
Why?
|
| Japan | 1 | 2016 | 1417 | 0.020 |
Why?
|
| Valine | 1 | 2013 | 410 | 0.020 |
Why?
|
| Cardia | 1 | 2011 | 61 | 0.020 |
Why?
|
| Vaccination | 1 | 2023 | 3434 | 0.020 |
Why?
|
| Tissue Embedding | 1 | 2011 | 43 | 0.020 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2012 | 148 | 0.020 |
Why?
|
| Case-Control Studies | 3 | 2020 | 22248 | 0.020 |
Why?
|
| Membrane Transport Proteins | 1 | 2016 | 1029 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2019 | 1536 | 0.020 |
Why?
|
| DNA-Cytosine Methylases | 1 | 2010 | 17 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 3552 | 0.020 |
Why?
|
| Azacitidine | 1 | 2012 | 335 | 0.020 |
Why?
|
| Mutagenesis | 2 | 2008 | 1228 | 0.020 |
Why?
|
| Neuroglia | 1 | 2016 | 960 | 0.020 |
Why?
|
| Prostatic Neoplasms | 2 | 2011 | 11094 | 0.020 |
Why?
|
| Veratrum Alkaloids | 1 | 2010 | 23 | 0.020 |
Why?
|
| Cytarabine | 1 | 2012 | 696 | 0.020 |
Why?
|
| DNA Repair | 1 | 2000 | 2050 | 0.020 |
Why?
|
| Introns | 1 | 2013 | 966 | 0.020 |
Why?
|
| Heterozygote | 2 | 2007 | 2795 | 0.020 |
Why?
|
| Culture | 1 | 2014 | 622 | 0.020 |
Why?
|
| Liver | 1 | 2006 | 7571 | 0.020 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2013 | 661 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2012 | 630 | 0.020 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 2270 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2011 | 655 | 0.020 |
Why?
|
| Organophosphorus Compounds | 1 | 2011 | 209 | 0.020 |
Why?
|
| Pulmonary Alveoli | 1 | 2013 | 665 | 0.020 |
Why?
|
| Western World | 1 | 2009 | 26 | 0.020 |
Why?
|
| Mutant Proteins | 1 | 2011 | 487 | 0.020 |
Why?
|
| Adenosine Triphosphatases | 1 | 2014 | 840 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2018 | 36567 | 0.020 |
Why?
|
| Patient Selection | 2 | 2012 | 4252 | 0.020 |
Why?
|
| Immunotherapy | 2 | 2016 | 4747 | 0.020 |
Why?
|
| Smad2 Protein | 1 | 2009 | 144 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2011 | 545 | 0.020 |
Why?
|
| Stem Cells | 1 | 2022 | 3537 | 0.020 |
Why?
|
| Neurosecretory Systems | 1 | 2011 | 223 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2023 | 6259 | 0.020 |
Why?
|
| Neural Stem Cells | 1 | 2016 | 895 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2022 | 8728 | 0.020 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2014 | 1143 | 0.020 |
Why?
|
| Microfluidics | 1 | 2014 | 650 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2013 | 1756 | 0.020 |
Why?
|
| Pregnancy | 1 | 2011 | 30237 | 0.020 |
Why?
|
| DNA | 1 | 2023 | 7208 | 0.020 |
Why?
|
| Colonic Polyps | 1 | 2014 | 557 | 0.020 |
Why?
|
| Cell Dedifferentiation | 1 | 2009 | 125 | 0.020 |
Why?
|
| Phylogeny | 1 | 2016 | 2840 | 0.020 |
Why?
|
| Canada | 1 | 2014 | 2126 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2016 | 8926 | 0.020 |
Why?
|
| Green Fluorescent Proteins | 2 | 2008 | 2062 | 0.020 |
Why?
|
| Radiation Dosage | 1 | 2017 | 1957 | 0.020 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2011 | 332 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 1749 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2014 | 2921 | 0.020 |
Why?
|
| Cell Separation | 1 | 2014 | 1718 | 0.020 |
Why?
|
| Co-Repressor Proteins | 1 | 2009 | 190 | 0.020 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 1997 | 2205 | 0.020 |
Why?
|
| Chromatin | 1 | 2020 | 2977 | 0.020 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2009 | 304 | 0.020 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 2077 | 0.020 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2010 | 268 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2017 | 1884 | 0.020 |
Why?
|
| Heterochromatin | 1 | 2011 | 294 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 2015 | 1895 | 0.020 |
Why?
|
| Microglia | 1 | 2017 | 1370 | 0.020 |
Why?
|
| Gadolinium | 1 | 2013 | 964 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2013 | 2846 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2015 | 1512 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2019 | 2902 | 0.020 |
Why?
|
| Australia | 1 | 2011 | 1263 | 0.020 |
Why?
|
| Autophagy | 1 | 2015 | 1346 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2016 | 2926 | 0.020 |
Why?
|
| Carcinoma, Large Cell | 1 | 2008 | 114 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 1852 | 0.020 |
Why?
|
| Intranuclear Inclusion Bodies | 1 | 2007 | 34 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2022 | 4970 | 0.020 |
Why?
|
| Glutamic Acid | 1 | 2013 | 1181 | 0.020 |
Why?
|
| Leukocyte Count | 1 | 2011 | 1606 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 1892 | 0.020 |
Why?
|
| Ribonucleases | 1 | 2007 | 266 | 0.020 |
Why?
|
| Hospitals | 1 | 2020 | 3888 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2014 | 1646 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 3432 | 0.020 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2009 | 616 | 0.020 |
Why?
|
| Cell Nucleolus | 1 | 2007 | 156 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 2746 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2017 | 2171 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2009 | 1697 | 0.020 |
Why?
|
| C-Peptide | 1 | 2008 | 443 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 2901 | 0.020 |
Why?
|
| Antigens, CD | 1 | 1997 | 4032 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2011 | 1733 | 0.020 |
Why?
|
| Fibroblasts | 2 | 2011 | 4166 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 1999 | 9547 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2011 | 1688 | 0.020 |
Why?
|
| Lymphokines | 1 | 2009 | 924 | 0.020 |
Why?
|
| Asia | 1 | 2007 | 629 | 0.020 |
Why?
|
| Comorbidity | 1 | 2020 | 10580 | 0.020 |
Why?
|
| Fibrosis | 1 | 2013 | 2077 | 0.020 |
Why?
|
| Pan troglodytes | 1 | 2006 | 224 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2013 | 1727 | 0.020 |
Why?
|
| CpG Islands | 1 | 2010 | 1208 | 0.020 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2008 | 335 | 0.020 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2010 | 1057 | 0.020 |
Why?
|
| Factor V | 1 | 2006 | 168 | 0.020 |
Why?
|
| Portal Vein | 1 | 2008 | 437 | 0.020 |
Why?
|
| Creatinine | 1 | 2011 | 1917 | 0.020 |
Why?
|
| Geography | 1 | 2007 | 651 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2010 | 771 | 0.020 |
Why?
|
| Endocytosis | 2 | 2000 | 951 | 0.020 |
Why?
|
| Sulfonamides | 1 | 2015 | 1982 | 0.020 |
Why?
|
| Cadherins | 1 | 2009 | 902 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2008 | 840 | 0.010 |
Why?
|
| Lectins | 1 | 2006 | 490 | 0.010 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2006 | 564 | 0.010 |
Why?
|
| Liver Function Tests | 1 | 2006 | 527 | 0.010 |
Why?
|
| Adipokines | 1 | 2006 | 308 | 0.010 |
Why?
|
| Energy Metabolism | 1 | 2015 | 2903 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 2704 | 0.010 |
Why?
|
| Anticoagulants | 1 | 2020 | 4855 | 0.010 |
Why?
|
| Genetics, Population | 1 | 2009 | 943 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2014 | 2839 | 0.010 |
Why?
|
| Ascites | 1 | 2006 | 336 | 0.010 |
Why?
|
| Precancerous Conditions | 1 | 2011 | 980 | 0.010 |
Why?
|
| Genomic Instability | 1 | 2008 | 716 | 0.010 |
Why?
|
| Observer Variation | 1 | 2010 | 2614 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2018 | 3236 | 0.010 |
Why?
|
| Acute Disease | 2 | 2012 | 7241 | 0.010 |
Why?
|
| Single-Blind Method | 1 | 2007 | 1587 | 0.010 |
Why?
|
| Ovarian Neoplasms | 2 | 2011 | 4904 | 0.010 |
Why?
|
| Atrophy | 1 | 2008 | 1631 | 0.010 |
Why?
|
| Vena Cava, Inferior | 1 | 2006 | 463 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 1331 | 0.010 |
Why?
|
| Janus Kinase 2 | 1 | 2006 | 562 | 0.010 |
Why?
|
| Aging | 1 | 2022 | 8731 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 15908 | 0.010 |
Why?
|
| Motor Neurons | 1 | 2007 | 869 | 0.010 |
Why?
|
| Models, Biological | 1 | 1999 | 9461 | 0.010 |
Why?
|
| Recurrence | 1 | 2015 | 8507 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2010 | 6214 | 0.010 |
Why?
|
| Ligands | 1 | 2009 | 3275 | 0.010 |
Why?
|
| Microfluidic Analytical Techniques | 1 | 2008 | 789 | 0.010 |
Why?
|
| Macrophages | 1 | 2017 | 5783 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2008 | 2603 | 0.010 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2007 | 1131 | 0.010 |
Why?
|
| Species Specificity | 1 | 2006 | 2413 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 26310 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 2006 | 1525 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 10384 | 0.010 |
Why?
|
| Haplotypes | 1 | 2007 | 2727 | 0.010 |
Why?
|
| Haloperidol | 1 | 1983 | 394 | 0.010 |
Why?
|
| Antibodies | 1 | 2009 | 2421 | 0.010 |
Why?
|
| Mass Screening | 1 | 2017 | 5454 | 0.010 |
Why?
|
| Germ-Line Mutation | 1 | 2009 | 1885 | 0.010 |
Why?
|
| Apolipoproteins E | 1 | 2006 | 1459 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2006 | 1144 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2011 | 5890 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2007 | 1368 | 0.010 |
Why?
|
| Zebrafish Proteins | 1 | 2006 | 1018 | 0.010 |
Why?
|
| Prostate-Specific Antigen | 1 | 2010 | 2463 | 0.010 |
Why?
|
| Fetus | 1 | 2007 | 1878 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 2011 | 3041 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 2 | 1999 | 3738 | 0.010 |
Why?
|
| Contrast Media | 1 | 2013 | 5329 | 0.010 |
Why?
|
| London | 1 | 2000 | 233 | 0.010 |
Why?
|
| Spinal Cord | 1 | 2007 | 1811 | 0.010 |
Why?
|
| p21-Activated Kinases | 1 | 2000 | 127 | 0.010 |
Why?
|
| Homosexuality | 1 | 2000 | 268 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2006 | 2201 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2000 | 861 | 0.010 |
Why?
|
| HLA-B7 Antigen | 1 | 1998 | 48 | 0.010 |
Why?
|
| Gene Duplication | 1 | 2000 | 315 | 0.010 |
Why?
|
| Clathrin | 1 | 1999 | 258 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2000 | 928 | 0.010 |
Why?
|
| Evolution, Molecular | 1 | 2006 | 1892 | 0.010 |
Why?
|
| Macaca | 1 | 1999 | 413 | 0.010 |
Why?
|
| Logistic Models | 1 | 2012 | 13278 | 0.010 |
Why?
|
| Spinal Cord Diseases | 1 | 1980 | 291 | 0.010 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2010 | 3359 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2011 | 7609 | 0.010 |
Why?
|
| Golgi Apparatus | 1 | 1998 | 405 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 1999 | 839 | 0.010 |
Why?
|
| Prevalence | 1 | 2013 | 15835 | 0.010 |
Why?
|
| Surface Properties | 1 | 1999 | 1153 | 0.010 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 3531 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1999 | 1677 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2013 | 11920 | 0.010 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 3108 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2000 | 2746 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2007 | 3581 | 0.010 |
Why?
|
| src-Family Kinases | 1 | 1997 | 539 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1999 | 2478 | 0.010 |
Why?
|
| Sarcoidosis | 1 | 1980 | 535 | 0.010 |
Why?
|
| Insulin | 1 | 2008 | 6608 | 0.010 |
Why?
|
| Cells, Cultured | 2 | 2000 | 18984 | 0.010 |
Why?
|
| HIV Infections | 1 | 2000 | 17536 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2006 | 5992 | 0.010 |
Why?
|
| Infant | 1 | 2012 | 36461 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2011 | 24295 | 0.010 |
Why?
|
| Lung Diseases | 1 | 1980 | 1941 | 0.010 |
Why?
|
| Cell Membrane | 1 | 1998 | 3641 | 0.000 |
Why?
|
| Mice, Inbred C57BL | 1 | 2007 | 22352 | 0.000 |
Why?
|
| Schizophrenia | 1 | 1983 | 6976 | 0.000 |
Why?
|
| Prolactin | 1 | 1983 | 627 | 0.000 |
Why?
|
| Myelography | 1 | 1980 | 72 | 0.000 |
Why?
|
| Schizophrenic Psychology | 1 | 1983 | 1647 | 0.000 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1983 | 6020 | 0.000 |
Why?
|